Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Available at: www.fda.gov/media/131878/download. Epilepsy Behav.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

NOVEMBER 24, 2019

Severe treatment-resistant epilepsy. Do not offer CBD to manage chronic pain in adults unless as part of a clinical trial. 1.4 Severe treatment-resistant epilepsy. NICE has made research recommendations on the use of cannabis-based medicinal products for severe treatment-resistant epilepsy. Rationale and impact.

Medicine 59

Medicine Chronic Pain Research and Development Treatment 59

Cannabis Law Report

JULY 15, 2022

The schedule eight pharmaceutical medicine has gained federal approval to treat conditions including cancer-related pain, nausea and vomiting, multiple sclerosis and epilepsy, and for use in palliative care. “Not just the perimeter security, but also the safety and security onsite is paramount.”

Medicine 52

Medicine Patients Media Supply Chain 52

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Refractory paediatric epilepsy. At the same time, the outlook on cannabis research data is largely positive. Conclusions.

Research and Development 52

Research and Development Medicine Access Media 52